Cod­ed cal­en­dar in­vites, covert emails and delet­ed doc­u­ments: Pfiz­er sues ex-em­ploy­ees for al­leged­ly steal­ing trade se­crets

When Re­gor Ther­a­peu­tics un­veiled a col­lab­o­ra­tion back in De­cem­ber with Eli Lil­ly to dis­cov­er and de­vel­op new drugs for meta­bol­ic dis­or­ders, founder and CEO Xi­ayang Qiu tout­ed the deal — which gave it $50 mil­lion up­front and could be worth up to $1.5 bil­lion to­tal — as a recog­ni­tion to the “world-class re­search or­ga­ni­za­tion” and core tech­nol­o­gy his team had built in just a lit­tle over three years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER